<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03486327</url>
  </required_header>
  <id_info>
    <org_study_id>BR55-110</org_study_id>
    <nct_id>NCT03486327</nct_id>
  </id_info>
  <brief_title>Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions</brief_title>
  <official_title>Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bracco Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Bracco Diagnostics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, single center, open label, parallel-dose, and prospective study of&#xD;
      BR55 CEUS for characterization of solid pancreatic lesions in subjects with suspected PDAC&#xD;
      using transabdominal US.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately twenty-four (24) subjects with suspected PDAC and scheduled to undergo surgical&#xD;
      resection within 30 days (but not before 24 hours) after the transabdominal BR55 CEUS&#xD;
      examination will be enrolled into 3 dose groups, 0.03, 0.05, and 0.08 mL/kg, with a maximum&#xD;
      of 8 patients in each dose group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 19, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Up to 24 subjects will be enrolled into 3 dose groups starting with the lowest dose group as follows: Dose group 0.03mL/kg, dose group 0.05mL/kg and dose group 0.08mL/kg/, with a maximum of 8 patients in each dose group.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Visual assessment of enhancement</measure>
    <time_frame>1 Day</time_frame>
    <description>BR55-enhanced images will be visually assessed using a 3-point scale (no enhancement, weak enhancement, strong enhancement).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Adverse Events</measure>
    <time_frame>2 Days</time_frame>
    <description>Number of participants who received the contrast agent and experienced an adverse event.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>0.03mL/kg Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group of up to 8 subjects to receive a single dose of BR55 at 0.03mL/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.05mL/kg Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group of up to 8 subjects to receive a single dose of BR55 at 0.05mL/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.08mL/kg Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group of 8 subjects to receive a single dose of BR55 at 0.08mL/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BR55</intervention_name>
    <description>A novel targeted ultrasound contrast agent</description>
    <arm_group_label>0.03mL/kg Dose Group</arm_group_label>
    <arm_group_label>0.05mL/kg Dose Group</arm_group_label>
    <arm_group_label>0.08mL/kg Dose Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Enroll a subject in this study if the subject meets the following inclusion criteria:&#xD;
&#xD;
          -  Is at least 18 years of age;&#xD;
&#xD;
          -  Has at least one solid pancreatic lesion;&#xD;
&#xD;
          -  Is scheduled to undergo surgical resection for suspected PDAC not earlier than 24&#xD;
             hours and not later than 30 days following BR55 administration;&#xD;
&#xD;
          -  Provides written Informed Consent and is willing to comply with protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclude a subject from this study if the subject does not fulfill the inclusion criteria,&#xD;
        or if any of the following conditions are observed:&#xD;
&#xD;
          -  Is a pregnant or lactating female. Exclude the possibility of pregnancy:&#xD;
&#xD;
               -  by testing on site at the institution (serum Î²HCG) within 24 hours prior to the&#xD;
                  start of IP administration,&#xD;
&#xD;
               -  by surgical history (e.g., tubal ligation or hysterectomy),&#xD;
&#xD;
               -  by post-menopausal status with a minimum 1 year without menses;&#xD;
&#xD;
          -  Has undergone prior systemic therapy for pancreatic cancer;&#xD;
&#xD;
          -  Has history of any concurrent malignancy;&#xD;
&#xD;
          -  Has history of any clinically unstable cardiac condition including class III/IV&#xD;
             congestive heart failure;&#xD;
&#xD;
          -  Has had any severe cardiac rhythm disorders within 7 days prior to enrolment;&#xD;
&#xD;
          -  Has severe pulmonary hypertension (pulmonary artery pressure &gt; 90mmHg) or uncontrolled&#xD;
             systemic hypertension and/or respiratory distress syndrome;&#xD;
&#xD;
          -  Has open and/or non-healing wounds in the chest, abdomen and pelvis;&#xD;
&#xD;
          -  Has other systemic vascular abnormalities associated with neovascularization, such as&#xD;
             macular degeneration, that in the opinion of the investigator could significantly&#xD;
             affect the ability to evaluate the effects of BR55;&#xD;
&#xD;
          -  Is participating in a clinical trial or has participated in another trial with an&#xD;
             investigational compound within the past 30 days prior to enrolment;&#xD;
&#xD;
          -  Has previously been enrolled in and completed this study;&#xD;
&#xD;
          -  Has any known allergy to one or more of the ingredients of the IP or to any other&#xD;
             contrast media;&#xD;
&#xD;
          -  Is determined by the Investigator that the subject is clinically unsuitable for the&#xD;
             study;&#xD;
&#xD;
          -  Has had major surgery, including laparoscopic surgery within 3 months prior to&#xD;
             enrolment;&#xD;
&#xD;
          -  Has history of pancreatic surgery (e.g., cyst removal);&#xD;
&#xD;
          -  Has acute pancreatic abnormalities (acute pancreatitis or trauma).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Luigia Storto, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bracco Diagnostics, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Yureneva, MD</last_name>
    <phone>609-514-2554</phone>
    <email>julia.yureneva@diag.bracco.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahima Goel</last_name>
      <phone>650-723-0371</phone>
      <email>mahimag@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Walter Park, MD</last_name>
      <phone>(650)-723-4102</phone>
      <email>wgpark@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Aya Kamaya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aya Kamaya</last_name>
      <phone>650-723-8463</phone>
      <email>kamaya@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Aya Kamaya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2018</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

